Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Palmitic acid
Price: Check
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang
Email: sales@echemcloud.com

2411216-42-5

2411216-42-5 structure

2411216-42-5 structure

Name: sRANKL-IN-2
Chemical Name: sRANKL-IN-2
CAS Number: 2411216-42-5
Molecular Formula: C₁₈H₁₈N₄O₇S
Molecular Weight: 434.42
Catalog: Signaling Pathways Apoptosis Apoptosis
Create Date: 2022-11-21 21:31:39
Modify Date: 2024-01-17 20:30:06
sRANKL-IN-2 (Compound S3-05) is a selective and orally active soluble RANKL (sRANKL) inhibitor with an IC50 of 0.41 μM. sRANKL-IN-2 can be used for the research of osteoporosis[1].

Name	sRANKL-IN-2

Description	sRANKL-IN-2 (Compound S3-05) is a selective and orally active soluble RANKL (sRANKL) inhibitor with an IC50 of 0.41 μM. sRANKL-IN-2 can be used for the research of osteoporosis[1].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Inflammation/Immunology
Target	soluble RANKL[1]
In Vitro	sRANKL-IN-2 (Compound S3-05) (0.03-10 μM; 24 h) induces mature osteoclasts apoptosis and attenuates bone resorption in a dose-dependent manner[1]. sRANKL-IN-2 (0-10 μM; 14 days) increases cell proliferation and mineralization in mouse embryonic mesenchymal stem cell line C3H10T1/2 or human primary osteoblasts cells with osteogenic differentiation medium[1]. Apoptosis Analysis[1] Cell Line: Mature osteoclasts Concentration: 0.03, 0.1, 0.3, 1, 3 and 10 μM Incubation Time: 24 h Result: Significantly increased apoptosis of mature osteoclasts with an EC50 of 0.53 μM. Cell Proliferation Assay[1] Cell Line: C3H10T12 cells Concentration: 0.08, 0.28, 0.92, 3.03 and 10 μM Incubation Time: 14 days Result: Increased cell proliferation and mineralization in mouse embryonic mesenchymal stem cell line C3H10T1/2.
In Vivo	sRANKL-IN-2 (Compound S3-05) (10 mg/kg/d; i.g.; 12 weeks) shows anti-osteoporosis activity in ovariectomy rats[1]. Animal Model: Female SD ovariectomy (OVX) rats[1] Dosage: 10 mg/kg/d Administration: Oral administraton, 12 weeks Result: Reduced bone loss, improved trabecular osteoporosis parameters, increased the bone volume / total volume (BV/TV). Animal Model: 28-week-old and 280 g∼370 g weight male SD (Sprague Dawley) rats[1] Dosage: 10 mg/kg Administration: Oral gavage (Pharmacokinetic Study) Result: The pharmacokinetic parameters of sRANKL-IN-2[1] sRANKL-IN-2 AUC (hr*μg/mL) 0.38 ± 0.23 Cmax (μg/mL) 0.06 ± 0.01 T1/2 (h) 10.62 ± 2.31
References	[1]. Huang D, et al. Identification of a binding site on soluble RANKL that can be targeted to inhibit soluble RANK-RANKL interactions and treat osteoporosis. Nat Commun. 2022 Sep 12;13(1):5338.

Molecular Formula	C₁₈H₁₈N₄O₇S
Molecular Weight	434.42

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.